Study Title
Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989–2012: a matched case– control study
British Medical Journal

Jiajia Zhang, Charles Haines, Alastair J M Watson, Andrew r Hart, Mary Jane Platt, Drew M Pardoll, Sara E Cosgrove, Kelly A Gebo, Cynthia L Sears


Microbiome dysbiosis predisposes to colorectal cancer (crc), but a population-based study of oral antibiotic exposure and risk patterns is lacking.
To assess the association between oral antibiotic use and crc risk.
A matched case–control study (incident crc cases and up to five matched controls) was performed using the clinical Practice research Datalink from 1989 to 2012.
28980 crc cases and 137077 controls were identified. Oral antibiotic use was associated with crc risk, but effects differed by anatomical location. antibiotic use increased the risk of colon cancer in a dose-dependent fashion (ptrend less than 0.001). the risk was observed after minimal use, and was greatest in the proximal colon and with antibiotics with anti-anaerobic activity. in contrast, an inverse association was detected between antibiotic use and rectal cancers (p trend=0.003), particularly with length of antibiotic exposure greater than 60 days (adjusted Or (aOr), 0.85, 95% ci 0.79 to 0.93) as compared with no antibiotic exposure. Penicillins, particularly ampicillin/amoxicillin increased the risk of colon cancer (aOr=1.09 (1.05 to 1.13)), whereas tetracyclines reduced the risk of rectal cancer (aOr=0.90 (0.84 to 0.97)). Significant interactions were detected between antibiotic use and tumour location (colon vs rectum, p interaction less
than 0.001; proximal colon versus distal colon, p interaction=0.019). the antibiotic–cancer association was found for antibiotic exposure occurring greater than 10 years before diagnosis (aOr=1.17 (1.06 to 1.31)).
Oral antibiotic use is associated with an increased risk of colon cancer but a reduced risk of rectal cancer. this effect heterogeneity may suggest differences in gut microbiota and carcinogenesis mechanisms along the lower intestinal tract.

June 21, 2019
View study

Share This

Related Topics

MicrobiomeAntibioticsColon CancerCancer

Dr. Perlmutter is one of the leading lights in medicine today, illuminating the path for solving chronic illness

Mark Hyman, MD